by Rod Raynovich | Apr 4, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Cubist settles with TEVA on generic Cubicin. Cubist was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $22. Teva gets right to generic daptomycin MRSA product on 6/24/18 and admits Cubist patents are valid. Cubist Pharmaceuticals Settles CUBICIN...